Calcitonin vs Pasireotide
Overview
Calcitonin is primarily a bone & joint peptide, while Pasireotide is used for hormonal.
This page compares Calcitonin and Pasireotide across their primary use, typical dosing, reported benefits and side effects, and U.S. regulatory status. For the full monograph on either compound — mechanism of action, clinical research, and references — follow the article links.
Side-by-side comparison
| Calcitonin | Pasireotide | |
|---|---|---|
| Category | Bone & Joint | Hormonal |
| Regulatory status (US) | FDA approved | FDA approved |
| Typical dosage | 100-200 IU | 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) |
| Frequency | daily | Twice daily (SC formulation) or every 4 weeks (LAR formulation) |
| Reported benefits | Reduced bone loss, pain relief in bone diseases | Reduction of cortisol hypersecretion in Cushing's disease, normalization of GH and IGF-1 in acromegaly, pituitary tumor volume reduction, improvement of clinical signs of hypercortisolism |
| Reported side effects | Nasal irritation (spray form), nausea | Hyperglycemia, new-onset or worsening diabetes mellitus, diarrhea, nausea, cholelithiasis, QT interval prolongation, bradycardia, hepatic enzyme elevation, adrenal insufficiency (hypocortisolism) |
Key differences
Primary use. Calcitonin is categorised under Bone & Joint, while Pasireotide falls under Hormonal. Their differing categories mean they are usually chosen for different goals rather than as direct substitutes.
Regulatory status. Calcitonin: FDA-approved. Pasireotide: FDA-approved.
Dosing. Calcitonin is typically dosed at 100-200 IU (daily). Pasireotide is typically dosed at 0.6–0.9 mg SC twice daily (Cushing's disease, SC formulation) or 40–60 mg IM every 4 weeks (acromegaly, LAR); 10–40 mg IM every 4 weeks (Cushing's disease, LAR) (Twice daily (SC formulation) or every 4 weeks (LAR formulation)).
Can you stack them?
Some protocols combine peptides, but stacking Calcitonin and Pasireotide has not been validated for safety or efficacy in controlled trials. Combining compounds can change their effects and risks. Nothing here is medical advice — consult a qualified healthcare provider before starting or combining any protocol.
Frequently asked questions
- What is the difference between Calcitonin and Pasireotide?
- Calcitonin is primarily a bone & joint peptide, while Pasireotide is used for hormonal. Calcitonin is FDA-approved for one or more indications, whereas Pasireotide is FDA-approved for one or more indications.
- What is Calcitonin used for?
- FDA-approved bone resorption inhibitor.
- What is Pasireotide used for?
- Multi-receptor somatostatin analog (Signifor/Signifor LAR) FDA-approved for Cushing's disease and acromegaly.
- Can you take Calcitonin and Pasireotide together?
- Some users combine peptides within a single protocol, but stacking Calcitonin and Pasireotide has not been established as safe or effective in controlled trials. Neither this comparison nor PeptideSciences101 is medical advice — consult a qualified healthcare provider before combining any compounds.
- Is Calcitonin or Pasireotide FDA-approved?
- Calcitonin is FDA-approved for one or more indications. Pasireotide is FDA-approved for one or more indications.
Read the full articles
- Calcitonin — full monograph: mechanism, research, dosing & references
- Pasireotide — full monograph: mechanism, research, dosing & references